We recently published a list of Billionaire Paul Singer’s Top 12 Long-Term Stock Picks. In this article, we are going to take a look at where Bausch Health Companies Inc. (NYSE:BHC) stands against other Billionaire Paul Singer’s long-term stock picks.
The world’s “most feared investor,” Paul Singer, needs no introduction. He has built a reputation on Wall Street for his aggressive and litigious tactics that often generate significant shareholder value. While the 79-year-old billionaire investor is not as flashy or public as other activist investors, he has built a reputation for exploiting weaknesses in various asset classes.
Singer’s initial approach to investing was to target companies and even governments while purchasing extremely distressed debt. Therefore, he is best known as a “vulture capitalist” as a result of this tactic. Since then, he has diversified into a number of investment strategies, such as activist investing, portfolio management, and commodity trading.
READ ALSO: Billionaire Daniel Sundheim’s Top 15 Stock Picks Heading Into 2025 and Billionaire David Tepper’s Top 10 Stock Picks Heading into 2025.
Elliott Management is the investment firm that Singer founded in 1977 with $1.3 million. It has grown to become one of the most successful and feared activist hedge funds, with about $19 billion in portfolio value. The firm serves as the management affiliate for hedge funds Elliott Associates L.P and Elliott International Limited. The firm boasts of an annual average return of 14% since inception. Likewise, it has only lost money in the two years since its inception.
Elliott Associates is one of the most tracked hedge funds and it employs an activist investment strategy. It also acquires significant though minority stakes in underperforming and distressed companies or assets with a view of unlocking long-term value. In addition, the firm strives to influence company management through strategic initiatives such as cost cuts, management changes and business sales to maximize shareholder value.
Singer’s investment firm also purchased distressed sovereign debt from nations like Argentina and Peru in the 1990s. The investments resulted in multi-million dollar repayments following years of legal disputes. In 2016 Singer received a $2.4 billion payout after warring with Argentina’s government over bond payments. A 2018 article in The New Yorker magazine called him a “doomsday investor” for his strategies, including corporate debt plays in companies.
Paul Singer’s investment record speaks for itself. His hedge fund, Elliott Management, returned 5.9% in 2022 as the S&P 500 went down 19%. Nevertheless, the firm underperformed in 2023, turning 4.3% compared to a 24% gain for the S&P 500. The underperformance came as Singer remained cautious amid concerns that The US economy was staring at an “extraordinarily dangerous and confusing period”.
In addition to the high interest rates, the billionaire hedge fund manager raised concerns about the overstretched valuations and prospects of paltry returns in the real estate and financial services sector. Fast forward, the equity market has continued to edge higher in 2024. The S&P 500 is already up by more than 30%, with valuations in various counters getting out of hand.
Nevertheless, macroeconomics shows improvement following the Federal Reserve’s bid to cut interest rates and steer the economy into a soft landing. As the Co-Chief Executive Officer and Co-Chief Investment Officer of Elliott Management, Singer has diversified his holdings as one of the ways of shrugging heightened volatility.
Consequently, billionaire Paul Singer’s top 12 long-term stock picks are spread across the basic materials, services and utilities segments. There are also healthcare, energy, and financial services holdings.
Our Methodology
To make the list of billionaire Paul Singer’s top 12 long-term stock picks, we scanned Elliott Management’s investment portfolio. We then settled on stocks the hedge fund has held for two years and more. Finally, we ranked the stocks in ascending order based on Elliott Management’s stake value.
At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A series of pharmaceutical and medical products in a warehouse, displaying the range of products available.
Bausch Health Companies Inc. (NYSE:BHC)
Elliott Management’s Stake Value: $93,843
Elliott Management First Major Purchase: 2022
Number of Hedge Fund Holders: 30
Bausch Health Companies Inc. (NYSE:BHC) is a diversified specialty pharmaceutical and medical device company. While the stock has been flat for the year, the company continues to demonstrate strength across its key business segments.
Bausch Health Companies Inc. (NYSE:BHC) delivered a sixth consecutive quarter of year-over-year growth in revenue and earnings on October 30, 2024. Revenues in the third quarter were up 12% to $2.51 billion. Its adjusted EBITDA increased to $909 million, beating analysts’ estimates by 9%. The better-than-expected results underscore Bausch Health Companies’ operational efficiency and capacity to generate revenue growth and profitability.
In keeping with its solid financial results and confidence in its continued growth trajectory, Bausch Health Companies Inc. (NYSE:BHC) has also increased its full-year 2024 guidance. Strong results in the Salix and International segments and developments in strategic initiatives like the Red Sea program and AI-driven customer engagement are essential factors in this strong financial health.
Additionally, Bausch Health Companies Inc. (NYSE:BHC) is divesting its equity stake in Bausch+Lomb (BLCO), which is expected to unlock significant value and streamline operations. BHC declared in August 2020 that it would split the eye health division, which included the Bausch + Lomb global Vision Care, Surgical, and Pharmaceuticals divisions, into a separate publicly traded company called Bausch + Lomb and separate it from the rest of the business.
Overall, BHC ranks 12th on our list of Billionaire Paul Singer’s long-term stock picks. While we acknowledge the potential of BHC, our conviction lies in the belief that under the radar AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BHC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.